Big Pharma has slowed down their buy outs of late
Post# of 155054
(Total Views: 741)
Posted On: 01/07/2021 8:20:37 PM
Re: MD VIROLOGIST #71778
Big Pharma has slowed down their buy outs of late because of using early promising phase 2 data that never came to fruition and many different pharmaceutical companies lost billions on buying on speculation. They want to see results that will be a guarantee or already have a BLA approved before buying. I think their motto became fool me once shame on you... fool me twice shame on me...
Big Pharma can’t stand any more buy out shame. They want the real deal already approved with BLA’s before they convince their board to buy a biotech. That is until recent covid purchases. But what drug has been a knock out? What drug will be the one to save many lives? Are they buying the right biotech? So many to choose from. Is it a last man standing for Severe to Critical? I think not...
It’s a great thing that we as Cytodyn have so many irons in the fire. Makes us really expensive after our first BLA achieves approval with so many more on the cusp of the pipeline just waiting for Mr. Rahman to file. Let’s think about this... filing for 8 approvals by either EUA or BLA and throw in a possible BTD. By the time Vyrologix is realized as a gem... it will be a possible mega equal to most big Pharma.
Then maybe a possible merger. The potential numbers by years end of $75-$100 makes us very expensive to buy. If we throw in the BTD for cancer in a 96 billion dollar market... We don’t need any stinking merger. We will be larger than half of the big Pharma’s by then. Maybe we buy out a few of them?
Big Pharma can’t stand any more buy out shame. They want the real deal already approved with BLA’s before they convince their board to buy a biotech. That is until recent covid purchases. But what drug has been a knock out? What drug will be the one to save many lives? Are they buying the right biotech? So many to choose from. Is it a last man standing for Severe to Critical? I think not...
It’s a great thing that we as Cytodyn have so many irons in the fire. Makes us really expensive after our first BLA achieves approval with so many more on the cusp of the pipeline just waiting for Mr. Rahman to file. Let’s think about this... filing for 8 approvals by either EUA or BLA and throw in a possible BTD. By the time Vyrologix is realized as a gem... it will be a possible mega equal to most big Pharma.
Then maybe a possible merger. The potential numbers by years end of $75-$100 makes us very expensive to buy. If we throw in the BTD for cancer in a 96 billion dollar market... We don’t need any stinking merger. We will be larger than half of the big Pharma’s by then. Maybe we buy out a few of them?
(8)
(0)